Do walking programs affect C-reactive protein, osteoprotegerin and soluble receptor activator of nuclear factor-kappaβ ligand?

Turkish Journal of Biochemistry

Volumn 34, Issue 3, 2009, Pages 178-186

  Esen, Hasan ^a   Büyükyazi, Gürbüz ^a   Ulman, Cevval ^a   Taneli, Fatma ^a   Ari, Zeki ^a   Gözlükaya, Fatma ^a   Tikiz, Hakan ^a  

^a CELAL BAYAR UNIVERSITY   (Turkey)

Author keywords

Estimated maximal oxygen consumption; Highly sensitive C reactive protein; Lipid profile; Middle aged men; Soluble receptor activator of nuclear factor kappa ligand; Walking exercises

Indexed keywords

C REACTIVE PROTEIN; LIPID; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN;

ADULT; ARTERY CALCIFICATION; ARTICLE; BODY COMPOSITION; BODY FAT; BODY MASS; BODY WEIGHT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; HUMAN; HUMAN EXPERIMENT; KINESIOTHERAPY; LIPID BLOOD LEVEL; MALE; NORMAL HUMAN; OXYGEN CONSUMPTION; PHYSICAL ACTIVITY; PROTEIN BLOOD LEVEL; WALKING;

EID: 73449138265     PISSN: None     EISSN: 1303829X     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. American Heart Association. (2002) Heart disease and stroke statistics - 2003 update, American Heart Association, Dallas (Tex):1-42.
2. Lakka TA, Venalainen JM, Raumaraa R, Salonen R, Tuomilehto J, Salonen JT. (1994) Relation of leisure-time physical activity and cardiorespiratory fitness to the risk of acute myocardial infarction. N. Engl J Med. 330:1549-54.
3. Thompson PD, Buchner D, Pina IL, Balady GJ, Williams MA, Marcus BH, Berra K, Blair SN, Costa F, Franklin B, Fletcher GF, Gordon NF, Pate RR, Rodriguez BL, Yancey AK, Wenger NK. (2003) Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease: a statement from the Council on Clinical Cardiology and the Council on Nutrition, Physical Activity, and Metabolism. Circulation. 107:3109-16.
4. Koh KK, Ahn JY, Choi YM, Han SH, Kim DS, Kim HS, Ahn TH, Choi IS, Shin EK. (2003) Vascular effects of step I diet in hypercholesterolemic patients with coronary artery disease. Am J Cardiol. 92:708-10.
5. Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH. (1998) Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation. 98:731-3.
6. Ridker PM, Stampfer MJ, Rifai N. (2001) Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA. 285:2481-5.
7. Ridker PM. (2003) High-sensitivity C-reactive protein and cardiovascular risk: Rationale for screening and primary prevention. Am J Cardiol. 92:17K-22K.
8. Mattusch F, Dufaux B, Heine O, Mertens I, Rost R. (2000) Reduction of the plasma concentration of C-reactive protein following nine months of endurance training. Int J Sports Med. 21:21-4.
9. Criswell D, Powers S, Dodd S, Lawler J, Edwards W. (1993) High intensity training-induced changes in skeletal muscle antioxidant enzyme activity. Med Sci Sports Exerc. 25:1135-40.
10. Leeuwenburgh C, Fiebig R, Chandwaney R, Ji LL. (1994) Aging and exercise training in skeletal muscle: responses of glutathione and antioxidant enzyme systems. Am J Physiol. 267: R439-R445.
11. Smith JK, Dykes R, Dougles JE, Krishnaswamy G, Berk S. (1999) Long-term exercise and atherogenic activity of blood mononuclear cells in persons at risk of developing ischemic heart disease. JAMA. 281:1722-7.
12. Fallon KE, Fallon SK, Boston T. (2001) The acute phase response and exercise: court and field sports. Br J Sports Med. 35:170-3.
13. Geffken DF, Cushman M, Burke GL, Polak JF, Sakkinen PA, Tracy RP. (2001) Association between physical activity and markers of inflammation in a healthy elderly population. Am J Epidemiol. 153:242-50.
14. Church TS, Barlow CE, Earnest CP, Kampert JB, Priest EL, Blair SN. (2002) Associations between cardiorespiratory fitness and C-reactive protein in men. Arterioscler Thromb Vasc Biol. 22:1869-76.
15. Abramson JL, Vaccarino V. (2002) Relationship between physical activity and inflammation among apparently healthy middle-aged and older US adults. Arch Intern Med. 162(11):1286-92.
16. Bassuk SS, Rifai N, Ridker PM. (2004) High-sensitivity C-reactive protein: Clinical importance. Curr Probl Cardiol. 29:439-93.
17. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Boyle WJ. (1997) Osteoprotegerin: a novel secreted protein involved in the regulation of bone density, Cell. 89:309-319.
18. Emery JG, McDonnell P, Burke MB, Deen KC, Lyn S, Silverman C, Dul E, Appelbaum ER, Eichman C, DiPrinzio R, Dodds RA, James IE, Rosenberg M, Lee JC, Young PR. (1998) Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL, J Biol Chem. 273:14363-7.
19. Schoppet M, Sattler AM, Schaefer JR. (2003) Increased osteoprotegerin serum levels in men with coronary artery disease. J Clin Endocrin Metabol. 88:1024-8.
20. Rhee EJ, Lee WY, Kim SY, Kim BJ, Sung KC, Kim BS, Kang JH, Oh KW, Oh ES, Baek KH, Kang MI, Woo HY, Park HS, Kim SW, Lee MH, Park JR. (2005) The relationship of serum osteoprotegerin levels with coronary artery disease severity, left ventricular hypertrophy and C-reactive protein. Clin Sci (Lond). 108:237-43.
21. Ueland T, Yndestad A, Oie E, Florholmen G, Halvorsen B, Froland SS, Simonsen S, Christensen G, Gullestad L, Aukrust P. (2005) Dysregulated osteoprotegerin/RANK ligand/RANK axis in clinical and experimental heart failure. Circulation. 111:2461-8.
22. Herrmann M, Herrmann W. (2004) The assessment of bone metabolism in female elite endurance athletes by biochemical bone markers. Clin Chem Lab Med. 42(12):1384-9.
23. Hinton PS, Rector RS, Thomas TR. (2006) Weight-bearing, aerobic exercise increases markers of bone formation during short-term weight loss in overweight and obese men and women. Metabolism. 55(12):1616-8.
24. Ziegler S, Niessner A, Richter B, Wirth S, Billensteiner E, Woloszczuk W, Slany J, Geyer G. (2005) Endurance running acutely raises plasma osteoprotegerin and lowers plasma receptor activator of nuclear factor kappa B ligand. Metabolism. 54(7):935-8.
25. Walker SN, Sechrist KR, Pender JN. (1995) The health- promoting lifestyle profile: Development and psychometric characteristics. Nurs Res. 36:76-81.
26. American College of Sports Medicine Position Stand. (1998) The recommended quantity and quality of exercise for developing and maintaining cardiorespiratory and muscular fitness, and flexibility in healthy adults. Med Sci Sports Exerc. 30:975-91.
27. Wei M, Macera CA, Hornung CA, Blair SN. (1997) Changes in lipids associated with change in regular exercise in free-living man. J Clin Epidemiol. 50:1137-42.
28. Gayda M, Brum C, Juneau M, Levesque S, Nigam A. (2008) Long-term cardiac rehabilitation and exercise training programs improve metabolic parameters in metabolic syndrome patients with and without coronary heart disease. Nutr Metab Cardiovasc Dis. 18:142-51.
29. Adner MM, Castelli WP. (1980) Elevated high-density lipoprotein levels in marathon runners. JAMA. 243:534-6.
30. Murphy MH, Murtagh EM, Boreham CAG, Hare LG, Nevill AM. (2006) The effect of a worksite based walking programme on cardiovascular risk in previously sedentary civil servants. BMC Public Health. 6:136-43.
31. Tchernof A, Nolan A, Sites CK, Ades PA, Poehlman ET. (2002) Weight loss reduces C-reactive protein levels in obese post-menopausal women. Circulation. 105:564-9.
32. Blair SN, KohlHW, Paffenbarger RS, Clark DG, Cooper KH, Gibbons LW. (1989) Physical fitness and all-cause mortality: Aprospective study of healthy men and women. JAMA. 262:2395-401.
33. Tracy R. (1997) Atherosclerosis, thrombosis and inflammation: a problem of linkage. Fibrinolysis. 11:1-5.
34. Munro J, Cotran R. (1988) The pathogenesis of atherosclerosis: atherogenesis and inflammation. Lab Invest. 58:249-61.
35. Libby P, Ridker PM. (2004) Inflammation and atherosclerosis: Role of C-reactive protein in risk assessment. Am J Med. 116(6):9-16.
36. Auer J, Berent R, Lassnig E, Eber B. (2002) C-reactive protein and coronary artery disease. Jpn Heart J. 43:607-19.
37. Tisi F, Hulse M, Chulakadabba A, Gosling P, Shearman CP. (1997) Exercise training for intermittent claudication: does it adversely affect biochemical markers of the exercise-induced inflammatory response? Eur J Vasc Endovasc Surg. 14:344-50.
38. Wegge JK, Roberts CK, Ngo TH, Barnard RJ. (2004) Effect of diet and exercise intervention on inflammatory and adhesion molecules in postmenopausal women on hormone replacement therapy and at risk for coronary artery disease. Metabolism. 53:377-81.
39. Collin-Osdoby P, Rothe L, Anderson F, Nelson M, Maloney W, Osdoby P. (2001) Receptor activator of NF-B and osteoprotegerin expression by human microvascular endothelial cells, regulation by inflammatory cytokines, and role in human osteoclastogenesis. J Biol Chem. 276:20659-72.
40. Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, Scully S, Tan HL, Xu W, Lacey DL, Boyle WJ, Simonet WS. (1998) Osteoprotegerin- deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 12:1260-8.
41. Rasmussen LM, Tarnow L, Hansen TK, Parving HH, Flyvbjerg A. (2006) Plasma osteoprotegerin levels are associated with glycaemic status, systolic blood pressure, kidney function and cardiovascular morbidity in type 1 diabetic patients. Eur J Endocrinol. 154:75-81.
42. Browner WS, Liu LY, Cummings SR. (2001) Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J Clin Endocrinol Metab. 86:631-7.
43. Gannage-Yared MH, Fares F, Semaan M, Khalife S, Jambart S. (2006) Circulating osteoprotegerin is correlated with lipid profile, insulin sensitivity, adiponectin and sex stereoids in an ageing male population. Clin Endocrinol. 64:652-8.